ProCE Banner Activity

Key COVID-19 Studies Influencing My Practice Following IDWeek 2022—Audio Recap

Podcast Episodes
Listen to expert insights from Princy N. Kumar, MD, and Paul E. Sax, MD, on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Released: November 18, 2022

Share

Faculty

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp

Faculty Disclosure

Primary Author

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP: researcher: American Gene Technologies, Gilead Sciences, GlaxoSmithKline, Merck; advisor: Gilead Sciences, Johnson & Johnson, Merck, Theratechnologies, ViiV; ownership interest: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer.